Fig. 1 · Structure

Documents & Downloads

AG-490

Cat. No. A10047 CAS 133550-30-8

EGFR inhibitor

AG 490 is a selective inhibitor of EGF receptor tyrosine kinase (IC50 values are 2 and 13.5 μM for EGFR and ErbB2 respectively). Also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.

In Stock

Publications for AG-490

1 publication citing this product

  1. Matozaki M, .et al. , Exp Cell Res, 2019, Feb 15. pii: S0014-4827(18)31030-9 PMID: 30776355

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

AG-490 has activity across JAK-family preparations under the tested conditions. At 100 μmol/L it reduced STAT3α phosphorylation in immunoprecipitate assays containing JAK1, JAK2, JAK3 or TYK2. This experiment supports broader JAK activity at that concentration, but does not establish a biochemical IC50 or selective JAK2 inhibition. [1]

AG-490 can also alter cytokine signaling through gp130 regulation. In rat RT4 schwannoma cells, 50 µM AG490 reduced gp130 protein without reducing its mRNA or accelerating surface-gp130 degradation. Delayed gp130 recovery after cycloheximide washout, together with eIF-2α phosphorylation and GADD153 induction, supported suppression of protein synthesis. These findings limit attribution of cellular STAT3 suppression solely to direct JAK2 inhibition. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
EGFR (Cell-free assay) 0.1 μM
JAK2 (Cell-free assay) ~10 μM
ErbB2 (Cell-free assay) 13.5 μM

Cellular Effect

Cell Line Activity Value Description Reference
HeLa IC50 > 100 μM Cytotoxicity against human HeLa cells after 48 hrs by MTT assay [PMID: 21185195]
HFF IC50 5584 nM Inhibition of fetal calf serum-induced proliferation of human foreskin fibroblast assessed as [3H]thymidine incorporation after 4 days by scintillation counting [PMID: 14593182]
HT-29 IC50 78.523 μM Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay [PMID: 21185195]
Sf9 IC50 > 10000 nM Inhibition of human recombinant GST-tagged JH1 domain (785 to1125) of JAK3 expressed in insect Sf9 cells by ELISA [PMID: 14593182]
T-cell IC50 3750 nM Inhibition of IL2-induced proliferation of human T cells assessed as [3H]thymidine incorporation after 72 hrs by scintillation counting [PMID: 14593182]
U-266 IC50 > 12.5 μM Antitumor activity against human U266 cells after 24 to 72 hrs by MTT assay [PMID: 22036213]

In Vitro Studies

Cellular responses depend on model and exposure. In RT4 cells, 50 µM AG490 reduced IL-6-induced STAT3 phosphorylation at the 3 and 5 h pretreatment points; MTT signal after one day was reported as 87.2%±5.3 of control, with the uncertainty type unspecified. In LPS-stimulated splenocytes, RAW264.7 and THP1 cells, 1–25 µM AG490 reduced TNF release. THP1 experiments showed reduced STAT3 Tyr705 phosphorylation without a significant reported change in Ser727 phosphorylation. [2,3]

JAK-family immunoprecipitate kinase assay

Biochemical assay · JAK1/JAK2 immunoprecipitates from HDLM-2 cells, JAK3 from L540 cells, and TYK2 from IFN-α-stimulated U266 cells; recombinant His-tagged STAT3α substrate [1]

At 100 μmol/L, AG490 reduced STAT3α phosphorylation in assays containing each of JAK1, JAK2, JAK3 and TYK2. This single-concentration comparator experiment does not establish an IC50 or a JAK2-selectivity ratio.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
STAT3α phosphorylation by JAK1, JAK2, JAK3 or TYK2 immunoprecipitatesQualitative result Reduced for all four JAK-family preparations at 100 μmol/L AG490[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 μmol/L
Exposure duration
1 hour preincubation at 30°C; kinase reaction for 30 minutes at 30°C
Method
Immunoprecipitates incubated with AG490, then 2 μg recombinant His-tagged STAT3α and 2 μmol/L ATP; SDS-PAGE/Western blot
Vehicle
DMSO; final fraction not reported
Co-treatment
NSC114792 was a separate comparator, not a combination treatment
Reported limits
AG490 source, final DMSO fraction, replicate count and quantitative inhibition values are not specified for Figure 2.
Methods and source locations

Compound reported in the paper: AG-490; Compound label in the paper: AG490

Results apply to the AG490 reagent reported in this model; they do not validate an Adooq batch or establish equivalence to separately sold E/Z mixtures.

Figure 2A-D (AG490 comparator lanes) and legend; Results: NSC114792 directly blocks JAK3 kinase activity; Methods: In vitro kinase assay

STAT3α phosphorylation by JAK1, JAK2, JAK3 or TYK2 immunoprecipitates: Phospho-STAT3 Western blot with total STAT3 and relevant JAK loading controls — Figure 2A-D (AG490 comparator lanes) and legend; Results: NSC114792 directly blocks JAK3 kinase activity; Methods: In vitro kinase assay

IL-6 signaling and gp130 turnover in RT4 cells

Cell-based study · Rat schwannoma RT4 cells [2]

AG490 reduced IL-6-induced STAT3 phosphorylation after prolonged pretreatment and reduced gp130 protein. Unchanged gp130 mRNA, lack of accelerated surface-gp130 degradation and delayed recovery after cycloheximide washout supported impaired gp130 synthesis. eIF-2α phosphorylation and GADD153 induction accompanied these changes.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IL-6-induced STAT3 Tyr705 phosphorylation and GFAP promoter activityQualitative result STAT3 phosphorylation reduced at 3 and 5 h pretreatment; GFAP reporter activation reduced[2]
gp130 protein abundance, mRNA, surface degradation and recovery after cycloheximideQualitative result gp130 protein decreased; mRNA unchanged; surface degradation not accelerated; post-washout recovery delayed[2]
eIF-2α phosphorylation and GADD153 expressionQualitative result Increased eIF-2α phosphorylation; GADD153 induction reported after 3 hrs[2]
MTT survival relative to control after 1 day at 50 µMRelative MTT signal 87.2%±5.3 of controls[2]

Literature-Reported Treatment Conditions

Treatment concentration
50 µM in time-course, turnover and reporter experiments; 0, 1, 5, 20, 50 and 100 µM in the Figure 2C dose panel
Exposure duration
STAT3: 0.25, 0.5, 1, 3 and 5 h pretreatment, then IL-6 for 15 min; gp130: 1, 3 and 6 h; reporter: 2 h pretreatment then 6 h IL-6
Method
IL-6 stimulation at 50 ng/ml; immunoblotting, RT-PCR, surface biotinylation and GFAP-promoter luciferase
Vehicle
Not specified for AG490 in the article
Co-treatment
Turnover/recovery experiments: cycloheximide 10 µM for 4 h, washed out before AG490; AG1478 and DTT were separate comparators
Reported limits
AG490 vehicle and final solvent fraction not reported; duration of the Figure 2C concentration series is not explicit. The variability definition for the text-only MTT value is unspecified.
Methods and source locations

Compound reported in the paper: AG-490; Compound label in the paper: AG490

Results apply to the AG490 reagent reported in this model; they do not validate an Adooq batch or establish equivalence to separately sold E/Z mixtures.

Figures 1A-D, 2A-D, 3A-B, 4A-B and 5A; Results; Methods: cell culture, survival assay, Western blot, luciferase, biotinylation and RT-PCR

IL-6-induced STAT3 Tyr705 phosphorylation and GFAP promoter activity: Western blots after 15 min IL-6; reporter after 2 h AG490 pretreatment plus 6 h IL-6; figure quantitative data mean±S.E., three independent experiments, *p<0.05 — Figure 1A-D and legend; Results: Long-term pretreatment

gp130 protein abundance, mRNA, surface degradation and recovery after cycloheximide: Western blot, RT-PCR and surface-biotinylation; no graph-derived numerical values — Figures 2-4; Methods: biotinylation and RT-PCR

eIF-2α phosphorylation and GADD153 expression: Western blot at 50 µM AG490; ER stress itself and the responsible upstream kinase were not established — Figure 5A and Results: Phosphorylation of eIF-2α

MTT survival relative to control after 1 day at 50 µM: MTT; text-only result, data not shown; uncertainty type and n for this specific value not explicitly defined — Results: Long-term pretreatment, final paragraph; Methods: Survival assay

Inflammatory responses to LPS in immune cells

Cell-based study · Primary mouse splenocytes, murine RAW264.7 macrophages and human THP1 monocytic cells [3]

AG490 reduced LPS-induced TNF release across the tested cell preparations. In THP1 cells it reduced STAT3 Tyr705 phosphorylation, while the authors reported no significant effect on Ser727 phosphorylation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
LPS-induced TNF releaseQualitative result Concentration-dependent reduction[3]
THP1 STAT3 Tyr705 and Ser727 phosphorylationReported phosphorylation inhibition Tyr705 phosphorylation inhibited by over 60% at 10 uM; no significant change in Ser727 phosphorylation reported[3]
Cell survival during TNF experimentsQualitative result Authors reported no cytotoxicity at tested concentrations[3]

Literature-Reported Treatment Conditions

Treatment concentration
1, 10 and 25 µM
Exposure duration
30 min before LPS; TNF measured 3 h after stimulation
Method
LPS stimulation followed by supernatant TNF ELISA; THP1 STAT3 Western blot
Vehicle
Ethanol described in general reagent methods; final cellular solvent fraction not stated
Co-treatment
No second inhibitor in the extracted monotherapy experiments; choline combination in Figure 1B not extracted
Reported limits
LPS dose for Figure 1C-D and post-LPS collection time for Figure 2B are not explicitly specified; Figure 2B labels LPS 400 ng/ml.
Methods and source locations

Compound reported in the paper: AG-490; Compound label in the paper: AG490

Results apply to the AG490 reagent reported in this model; they do not validate an Adooq batch or establish equivalence to separately sold E/Z mixtures.

Figures 1C-D and 2B and legends; Results: JAK2 inhibition blunted LPS-induced TNF production and prevented STAT3 phosphorylation; Methods: Cell cultures, Cytokine/STAT3 analyses

LPS-induced TNF release: ELISA at 3 h; three experiments; Figure 1C marks *p<0.01 versus LPS; quantitative curves not digitized — Figure 1C-D and legend; Methods: Cytokine analyses

THP1 STAT3 Tyr705 and Ser727 phosphorylation: Western blot after AG490 pretreatment and LPS 400 ng/ml; value taken from Results, not estimated from image — Figure 2B; Results: JAK2 inhibition prevented STAT3 tyrosine phosphorylation

Cell survival during TNF experiments: MTT and trypan-blue exclusion; retain assay-limited conclusion, not general safety — Figure 1C-D and Results: JAK2 inhibition blunted LPS-induced TNF production

In Vivo Studies

In female NOD mice, AG490 at 1 mg/mouse intraperitoneally, three times weekly for 5 weeks and then weekly for 5 weeks, lowered diabetes incidence when treatment began at 4 or 8 weeks of age. In a separate cohort treated for 5 weeks from age 4 weeks, pancreatic insulitis scores did not significantly differ from vehicle controls. The incidence result therefore did not coincide with a demonstrated reduction in insulitis in that histology experiment. [4]

In mouse endotoxemia, AG490 pretreatment at 10 mg/kg intraperitoneally reduced serum TNF and TNF in lung and spleen, but not in liver or heart. Separate cohorts showed improved survival at 0.5 or 10 mg/kg. In polymicrobial sepsis induced by cecal ligation and puncture, 5 mg/kg AG490 given at 12 h, or at both 24 and 36 h after surgery, improved survival with antibiotic and fluid support. These studies report pharmacodynamic and survival endpoints rather than pharmacokinetic exposure. [3]

Pretreatment in mouse endotoxemia

Animal study · Male C57BL/6J mice, 6–8 weeks old; LPS endotoxemia (6 mg/kg, i.p.) [3]

AG490 pretreatment reduced serum TNF at 10 mg/kg and reduced TNF in lung and spleen, with no reported reduction in liver or heart. Separate survival cohorts showed improved survival at 0.5 and 10 mg/kg.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Serum and tissue TNF 90 min after LPSReported approximate TNF inhibition Serum ~50% inhibition; lung ~70%; spleen ~40% at 10 mg/kg; no reduction reported in liver or heart[3]
Survival after endotoxemiaSurvival comparison Improved survival; *p<0.038 (0.5 mg/kg), **p<0.0003 (10 mg/kg) versus control[3]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Single pretreatment, 30 min before LPS
Vehicle
Ethanol; Methods wording is “20 mM ethanol”; final administered solvent fraction and injection volume are not established
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
TNF dose response
1, 5 or 10 mg/kg for serum dose response; 10 mg/kg for tissue TNF
LPS with vehicle; unstimulated controlsLargest serum TNF effect at 10 mg/kg; tissue effect limited to lung and spleen among reported tissues.[3]
Survival cohorts
0.5 or 10 mg/kg
Control vehicle before LPSBoth doses improved survival; larger effect at 10 mg/kg.[3]
TNF dose response
Model: Male C57BL/6J mice, 6–8 weeks old; LPS endotoxemia (6 mg/kg, i.p.)
Treatment course: TNF collected 90 min after LPS
Reported limits: Final ethanol fraction and injection volume not reported; no plasma or tissue AG490 concentrations measured in the extracted design.
Survival cohorts
Model: Male C57BL/6J mice, 6–8 weeks old; LPS endotoxemia (6 mg/kg, i.p.)
Treatment course: Survival followed for 2 weeks
Reported limits: Final ethanol fraction and injection volume not reported; no plasma or tissue AG490 concentrations measured in the extracted design.
Methods and source locations

Compound reported in the paper: AG-490; Compound label in the paper: AG490

Results apply to the AG490 reagent reported in this model; they do not validate an Adooq batch or establish equivalence to separately sold E/Z mixtures.

Figure 4A-C and legend; Results: JAK2 inhibition prevented serum HMGB1 and rescued mice; Methods: Animals, Chemicals, Cytokine analyses

Serum and tissue TNF 90 min after LPS: TNF ELISA; tissue TNF normalized to protein; n=6/group, *p<0.05 versus LPS; approximate values are author-reported — Figure 4A-B; Results paragraph describing Figure 4

Survival after endotoxemia: Logrank test; n=20 animals/group; monitored 2 weeks, no late deaths reported; figure displays the first week — Figure 4C and legend

TNF dose response · Figure 4A-B and legend

Survival cohorts · Figure 4C and legend

Delayed treatment in polymicrobial sepsis

Animal study · Male C57BL/6J mice, 6–8 weeks old; cecal ligation and puncture (CLP) [3]

AG490 administered after CLP improved survival in two delayed-treatment schedules. All animals received antibiotic and fluid support described in the CLP methods.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Survival after established CLP sepsisSurvival comparison Improved survival with either delayed schedule; *p<0.01 versus control[3]

Conditions shared by the study groups

Route
Intraperitoneal
Vehicle
Ethanol; Methods wording is “20 mM ethanol”; final administered solvent fraction and injection volume are not established
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
12 h start
5 mg/kg
Vehicle-treated CLP mice with the same supportive regimenImproved survival; n=10/group; p<0.01.[3]
24 h start
5 mg/kg per administration
Vehicle-treated CLP mice with the same supportive regimenImproved survival; n=22/group; p<0.01.[3]
12 h start
Model: Male C57BL/6J mice, 6–8 weeks old; cecal ligation and puncture (CLP)
Frequency: Once, 12 h after CLP
Treatment course: One dose; survival monitored 2 weeks
Reported limits: Final ethanol fraction and injection volume not reported; no plasma or tissue AG490 concentrations measured in the extracted design.
24 h start
Model: Male C57BL/6J mice, 6–8 weeks old; cecal ligation and puncture (CLP)
Frequency: At 24 and 36 h after CLP
Treatment course: Two doses; survival monitored 2 weeks
Reported limits: Final ethanol fraction and injection volume not reported; no plasma or tissue AG490 concentrations measured in the extracted design.
Methods and source locations

Compound reported in the paper: AG-490; Compound label in the paper: AG490

Results apply to the AG490 reagent reported in this model; they do not validate an Adooq batch or establish equivalence to separately sold E/Z mixtures.

Figure 5C-D and legend; Results final paragraph before Figure 4; Methods: Cecal ligation and puncture

Survival after established CLP sepsis: Logrank test; n=10/group for 12 h schedule, n=22/group for 24/36 h schedule; monitored 2 weeks with no late deaths reported — Figure 5C-D and legend; Results CLP paragraph

12 h start · Figure 5C and Results CLP paragraph

24 h start · Figure 5D and Results CLP paragraph

Diabetes prevention in NOD mice

Animal study · Female NOD/LtJ mice starting at 4 or 8 weeks of age [4]

AG490 lowered diabetes incidence when treatment began at 4 or 8 weeks of age. The study defined diabetes as blood glucose >250 mg/dl on two consecutive tests 24 h apart.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Diabetes-free survival through week 30Diabetes incidence comparison p=0.02 for 4-week start; p=0.005 for 8-week start[4]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Three times/week for 5 weeks, then once/week for 5 additional weeks
Treatment course
10-week dosing schedule; incidence comparison at week 30
Vehicle
Sterile DMSO diluted with sterile PBS; final fraction and volume not reported
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Treatment beginning at 4 weeks
1 mg/mouse
DMSO/PBS vehicle n=13; untreated n=11; AG490 n=15Lower diabetes incidence than vehicle at week 30 (p=0.02).[4]
Treatment beginning at 8 weeks
1 mg/mouse
Vehicle control; n=10/groupLower diabetes incidence at week 30 (p=0.005).[4]
Treatment beginning at 4 weeks
Model: Female NOD/LtJ mice starting at 4 or 8 weeks of age; 4-week cohort
Reported limits: Final DMSO fraction and injection volume not reported; no AG490 exposure measurements.
Treatment beginning at 8 weeks
Model: Female NOD/LtJ mice starting at 4 or 8 weeks of age; 8-week cohort
Reported limits: Final DMSO fraction and injection volume not reported; no AG490 exposure measurements.
Methods and source locations

Compound reported in the paper: AG-490; Compound label in the paper: AG490

Results apply to the AG490 reagent reported in this model; they do not validate an Adooq batch or establish equivalence to separately sold E/Z mixtures.

Figure 1A-B and legend; Results: AG490 prevents development of autoimmune diabetes; Methods: Mice, Compound, Administration of AG490

Diabetes-free survival through week 30: Kaplan-Meier comparison as reported; blood glucose measured by ACCU-CHEK; no curve percentages inferred — Figure 1A-B and legend; Methods: Administration of AG490

Treatment beginning at 4 weeks · Figure 1A and legend; Methods: Compound and Administration

Treatment beginning at 8 weeks · Figure 1B and legend; Methods: Compound and Administration

Pancreatic insulitis after AG490 treatment

Animal study · Female NOD mice, treatment started at 4 weeks; separate histology cohort [4]

AG490 did not significantly change pancreatic insulitis scores in this separate cohort, despite the lower diabetes incidence observed in the prevention cohorts.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Pancreatic leukocyte infiltration/insulitis scoreHistological score comparison p=n.s.; no statistically significant difference[4]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Three times/week for 5 consecutive weeks
Treatment course
Sacrificed at week 10, described as one week after last injection
Vehicle
Sterile DMSO diluted with sterile PBS; final fraction and volume not reported
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Five-week treatment and week-10 histology
1 mg/mouse
Vehicle-treated NOD mice; n=5/groupNo significant change in insulitis score.[4]
Five-week treatment and week-10 histology
Model: Female NOD mice, treatment started at 4 weeks; separate histology cohort
Reported limits: Final DMSO fraction and injection volume not reported; no AG490 exposure measurements.
Methods and source locations

Compound reported in the paper: AG-490; Compound label in the paper: AG490

Results apply to the AG490 reagent reported in this model; they do not validate an Adooq batch or establish equivalence to separately sold E/Z mixtures.

Figure 4A and legend; Results: Administration of AG490 does not diminish leukocyte infiltration; Methods: Histology and immunofluorescence histochemistry, Compound

Pancreatic leukocyte infiltration/insulitis score: Two blinded investigators; average scores, ≥150 islets/group in two sections 100 µm apart; n=5 mice/group; score 0=intact/pre-insulitis, 1=<50% infiltration, 2=>50% infiltration — Figure 4A and legend; Methods: Histology

Five-week treatment and week-10 histology · Figure 4A legend; Methods: Compound

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 133550-30-8
Applications EGFR inhibitor
Formula C17H14N2O3
Molecular Weight 294.3
Synonyms Tyrphostin AG490
SMILES
O=C(NCC1=CC=CC=C1)/C(C#N)=C/C2=CC(O)=C(O)C=C2

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 54 mg/mL (183.48 mM)
Water Insoluble
Ethanol 6 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
5.93 mg/mL
Vehicle
5% DMSO+40% PEG300+5% Tween80+50% ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Kim BH, Jee JG, Yin CH, et al. NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3. Molecular cancer (2010). PMID: 20149240 DOI: 10.1186/1476-4598-9-36 Source material
  2. [2] Seo IA, Lee HK, Shin YK, et al. Janus Kinase 2 Inhibitor AG490 Inhibits the STAT3 Signaling Pathway by Suppressing Protein Translation of gp130. The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology (2009). PMID: 19885008 DOI: 10.4196/kjpp.2009.13.2.131 Source material
  3. [3] Peña G, Cai B, Deitch EA, et al. JAK2 inhibition prevents innate immune responses and rescues animals from sepsis. Journal of molecular medicine (Berlin, Germany) (2010). PMID: 20393690 DOI: 10.1007/s00109-010-0628-z Source material
  4. [4] Davoodi-Semiromi A, Wasserfall CH, Xia CQ, et al. The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice. PloS one (2012). PMID: 22615750 DOI: 10.1371/journal.pone.0036079 Source material

Publications

1 publication citing this product

  1. Matozaki M, .et al. , Exp Cell Res, 2019, Feb 15. pii: S0014-4827(18)31030-9 PMID: 30776355

Added to your cart

View Cart Checkout
Loading...